drugset / Trial / NCT03008148
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, phase II/III, open-label, randomized, parallel and standard chemoradiation-controlled study where eligible subjects will be randomized at 1:1 ratio to receive control treatment or study treatment. The primary objective of this trial is to evaluate the effect of add-on JP001 to standard chemoradiation in increasing overall survival (OS) on newly diagnosed glioblastoma (GBM) patients.
Timeline
- Start
- 2018-10-11
- Primary completion
- 2025-04
- Completion
- 2025-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siroquine | Unknown | — | Oral |
| Background | Temozolomide | Small molecule | 150 mg/m2 | — |
| Background | Temozolomide | Small molecule | 200 mg/m2 | — |